CY1115598T1 - Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα - Google Patents

Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα

Info

Publication number
CY1115598T1
CY1115598T1 CY20141100646T CY141100646T CY1115598T1 CY 1115598 T1 CY1115598 T1 CY 1115598T1 CY 20141100646 T CY20141100646 T CY 20141100646T CY 141100646 T CY141100646 T CY 141100646T CY 1115598 T1 CY1115598 T1 CY 1115598T1
Authority
CY
Cyprus
Prior art keywords
antigen
influenze
constructions
release bodies
release
Prior art date
Application number
CY20141100646T
Other languages
Greek (el)
English (en)
Inventor
Dominique Bonnet
Carlton B Brown
Bertrand Georges
Philip J Sizer
Original Assignee
Immune Targeting Systems (Its) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115598(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Targeting Systems (Its) Limited filed Critical Immune Targeting Systems (Its) Limited
Publication of CY1115598T1 publication Critical patent/CY1115598T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20141100646T 2007-08-31 2014-08-13 Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα CY1115598T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716992.3A GB0716992D0 (en) 2007-08-31 2007-08-31 Influenza antigen delivery vectors and constructs
EP08788477.1A EP2190474B1 (en) 2007-08-31 2008-08-29 Influenza antigen delivery vectors and constructs

Publications (1)

Publication Number Publication Date
CY1115598T1 true CY1115598T1 (el) 2017-01-04

Family

ID=38617093

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100646T CY1115598T1 (el) 2007-08-31 2014-08-13 Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα

Country Status (23)

Country Link
US (4) US8642531B2 (sl)
EP (2) EP2762164B1 (sl)
JP (5) JP5756630B2 (sl)
KR (3) KR101665141B1 (sl)
CN (1) CN101827607A (sl)
AR (1) AR068507A1 (sl)
AU (1) AU2008291974B2 (sl)
BR (1) BRPI0815836A2 (sl)
CA (1) CA2697729C (sl)
CL (1) CL2008002559A1 (sl)
CY (1) CY1115598T1 (sl)
DK (2) DK2190474T3 (sl)
EA (1) EA018765B1 (sl)
ES (2) ES2488941T3 (sl)
GB (2) GB0716992D0 (sl)
HK (1) HK1144153A1 (sl)
HR (1) HRP20140765T1 (sl)
MX (1) MX2010002335A (sl)
PL (1) PL2190474T3 (sl)
PT (1) PT2190474E (sl)
SI (1) SI2190474T1 (sl)
TW (2) TW201345551A (sl)
WO (1) WO2009027688A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CN102137675A (zh) 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
RU2013109273A (ru) 2010-08-03 2014-09-10 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммершлайзейшн Полипептиды, используемые для лечения и/или подавления инфекций, вызываемых вирусом гриппа
AU2011335551B2 (en) * 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP2800576A2 (en) 2012-03-13 2014-11-12 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
US20150250872A1 (en) 2012-09-21 2015-09-10 Frank Bedu-Addo Vaccine compositions and methods of use
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
US9771395B2 (en) 2014-03-21 2017-09-26 University Of Washington Enhanced influenza hemagglutinin binders
WO2015157189A1 (en) * 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
JP6103547B2 (ja) * 2015-01-09 2017-03-29 三菱電機株式会社 電子基板ユニット
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3257864A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Metabolically stable spexin peptide analogs
EP3257863A1 (en) * 2016-06-16 2017-12-20 Université de Strasbourg Flourous metabolically stable peptide analogs
KR20190073416A (ko) * 2016-10-05 2019-06-26 피디에스 바이오테크놀러지 코퍼레이션 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
EP3679056A1 (en) * 2017-09-08 2020-07-15 The University of Melbourne Methods and compositions for preventing influenza infection
EP3773710A4 (en) * 2018-04-04 2022-03-16 Altimmune Inc COMBINATIONS OF VACCINE COMPOSITIONS INDUCING T LYMPHOCYTES AND THEIR USES
JP7037994B2 (ja) 2018-04-11 2022-03-17 株式会社シマノ 制御装置、人力駆動車、および制御方法
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
EP4172897A1 (en) * 2020-06-29 2023-05-03 Seqirus UK Limited Adaptive vaccine stockpile
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065141A (en) 1960-08-24 1962-11-20 Albert E Gessler Separation of nucleoproteins and nucleic acids from aqueous protein mixtures
GB1193378A (en) 1967-04-11 1970-05-28 Rand Dev Corp Cancer Antigen Complexes
US3843443A (en) 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
US4332787A (en) 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
US4689398A (en) 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
US4716102A (en) 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
ES2044881T3 (es) 1986-06-12 1994-01-16 Behringwerke Ag Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
EP0257758B1 (en) 1986-08-07 1993-03-10 Minnesota Mining And Manufacturing Company Stable biologically active fluorochemical emulsions
US4954444A (en) 1987-03-02 1990-09-04 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5055562A (en) 1988-02-01 1991-10-08 Biomira, Inc. Fluorocarbon chain-containing antigenic conjugates
US5021551A (en) 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
WO1991017187A2 (en) 1990-04-18 1991-11-14 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
JP3895366B2 (ja) 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド ウィルス ワクチン
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
AU654481B2 (en) 1991-03-14 1994-11-10 British Technology Group Usa, Inc. Recombinant anticoccidial vaccine
EP0503203A1 (en) 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Novel thrombin inhibitors
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
CA2163652A1 (en) 1993-05-27 1994-12-08 Carol A. Nacy Compositions and methods for treating cancer and hyperproliferative disorders
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
EP0756604A1 (en) 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
GB9420146D0 (en) 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US6548046B1 (en) 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6069232A (en) 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6121123A (en) 1997-09-05 2000-09-19 Advanced Micro Devices, Inc. Gate pattern formation using a BARC as a hardmask
EP1023058A2 (en) 1997-10-24 2000-08-02 Alliance Pharmaceutical Corp. Amelioration of ischemic damage using synthetic oxygen carriers
EP1064022A4 (en) 1998-03-13 2004-09-29 Epimmune Inc HLA BINDING PEPTIDES AND THEIR APPLICATIONS
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
RU2218175C2 (ru) 2001-03-06 2003-12-10 Научно-исследовательский институт по изучению лепры Способ стимуляции образования антител при иммунизации лабораторных животных
WO2002072627A2 (en) 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US20050013826A1 (en) 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
ES2297688T3 (es) 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CN101116057B (zh) 2004-12-30 2011-10-05 英特尔公司 在多个指令定序器上基于指令集的线程执行机制
FR2883563B1 (fr) 2005-03-24 2007-06-01 Ts Pharma Sarl Nouveaux vecteurs cationiques bolaformes hemifluorocarbones et leurs applications
PT2478916T (pt) * 2006-01-27 2020-07-03 Seqirus Uk Ltd Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
US20090023895A1 (en) 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation

Also Published As

Publication number Publication date
HRP20140765T1 (hr) 2014-09-12
GB201005395D0 (en) 2010-05-12
US20140234356A1 (en) 2014-08-21
KR20170001729A (ko) 2017-01-04
GB2465733B (en) 2010-12-01
CL2008002559A1 (es) 2009-06-26
US20210316000A9 (en) 2021-10-14
GB2465733A (en) 2010-06-02
MX2010002335A (es) 2010-08-10
US20090191233A1 (en) 2009-07-30
AU2008291974B2 (en) 2012-06-28
CA2697729C (en) 2016-07-26
CN101827607A (zh) 2010-09-08
US20170049898A1 (en) 2017-02-23
EP2190474B1 (en) 2014-05-14
EP2762164B1 (en) 2019-05-08
JP6826027B2 (ja) 2021-02-03
TWI469790B (zh) 2015-01-21
SI2190474T1 (sl) 2014-09-30
BRPI0815836A2 (pt) 2015-03-03
CA2697729A1 (en) 2009-03-05
AR068507A1 (es) 2009-11-18
AU2008291974A1 (en) 2009-03-05
PL2190474T3 (pl) 2014-11-28
WO2009027688A1 (en) 2009-03-05
EP2190474A1 (en) 2010-06-02
TW200930400A (en) 2009-07-16
US10155049B2 (en) 2018-12-18
HK1144153A1 (en) 2011-01-28
ES2741729T3 (es) 2020-02-12
KR101736897B1 (ko) 2017-05-17
DK2762164T3 (da) 2019-08-12
EA018765B1 (ru) 2013-10-30
JP2010537961A (ja) 2010-12-09
US9446143B2 (en) 2016-09-20
KR101665141B1 (ko) 2016-10-25
KR20150074182A (ko) 2015-07-01
DK2190474T3 (da) 2014-08-18
JP2021001216A (ja) 2021-01-07
GB0716992D0 (en) 2007-10-10
KR20100067094A (ko) 2010-06-18
JP5756630B2 (ja) 2015-07-29
JP2013241414A (ja) 2013-12-05
EP2762164A1 (en) 2014-08-06
US20190142951A1 (en) 2019-05-16
JP2018076355A (ja) 2018-05-17
ES2488941T3 (es) 2014-09-01
EA201070329A1 (ru) 2010-10-29
JP2016155829A (ja) 2016-09-01
PT2190474E (pt) 2014-08-29
US8642531B2 (en) 2014-02-04
TW201345551A (zh) 2013-11-16

Similar Documents

Publication Publication Date Title
CY1115598T1 (el) Φορεις απελευθερωσης αντιγονου γριπης και κατασκευασματα
CY1113970T1 (el) Κατασκευες και φορεις μεταφορας αντιγονων
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
CY1119849T1 (el) Προ-συντηξης rsv f αντιγονα
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1118702T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY1119789T1 (el) Cgrp αντισωματα
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CO6670523A2 (es) Anticuerpos específicos para proteína de activación fibroblástica (fap), polinucleotidos que codifican dichos anticuerpos, y vectores y células huesped que comprenden dichos nucleótidos
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
IN2012DN06289A (sl)
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
DK2531213T3 (da) Molekylkompleks til målretning af antigener mod antigenpræsenterende celler samt deres anvendelser til vaccination
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CY1119164T1 (el) Πεπτιδια που προερχονται απο τον παραγοντα viii για χρηση στη θεραπεια της αιμορροφιλιας α